Adverse Effects of Statins

Frequency of Adverse Effects of Statins

Frequency category	Definition	Typical adverse effects
Very common	≥ 1 in 10	– (no consistently very common adverse effects across all statins)
Common	≥ 1 in 100 to < 1 in 10	Muscle pain (myalgia), joint pain, headache, gastrointestinal symptoms (nausea, abdominal pain, diarrhea), elevated liver enzymes
Uncommon	≥ 1 in 1,000 to < 1 in 100	Muscle weakness, fatigue, dizziness, skin rash, pruritus, sleep disturbances
Rare	≥ 1 in 10,000 to < 1 in 1,000	Myopathy, marked transaminase elevation, memory disturbances, peripheral neuropathy
Very rare	< 1 in 10,000	Rhabdomyolysis, liver failure, severe allergic reactions
Not known	Frequency cannot be estimated	Diabetes mellitus (especially in high-risk individuals), tendon disorders, immune-mediated necrotizing myopathy

Frequency categories follow the European Medicines Agency (EMA) classification.

Clinically Important Interpretation

Muscle symptoms are the most common clinically relevant adverse effect and are usually mild and reversible.
Severe complications (e.g., rhabdomyolysis) are very rare but occur more frequently with high doses, drug interactions, or renal impairment.
With correct indication, the cardiovascular benefit of statins clearly outweighs the risk of adverse effects.

Rosuvastatin – Frequency of Adverse Effects

Frequency	Adverse effects
Very common	–
Common	Headache, dizziness, abdominal pain, constipation, nausea, muscle pain (myalgia), asthenia, elevated CK levels
Uncommon	Skin rash, pruritus, urticaria
Rare	Myopathy, rhabdomyolysis, marked transaminase elevation, pancreatitis
Very rare	Liver failure, severe hypersensitivity reactions (e.g., angioedema), memory disturbances
Not known	Diabetes mellitus, peripheral neuropathy, immune-mediated necrotizing myopathy, tendon disorders

Special Features of Rosuvastatin

Slightly higher CK elevations compared with some other statins
Increased risk of muscle symptoms in individuals of Asian ancestry, in renal impairment, and at high doses (≥40 mg)
Fewer clinically relevant CYP interactions (not primarily metabolized via CYP3A4)

Atorvastatin – Frequency of Adverse Effects

Frequency	Adverse effects
Very common	–
Common	Nasopharyngitis, headache, gastrointestinal symptoms (diarrhea, nausea, dyspepsia), muscle pain, joint pain, elevated liver enzymes
Uncommon	Sleep disturbances, nightmares, dizziness, vomiting, skin rash, fatigue
Rare	Myopathy, rhabdomyolysis, hepatitis
Very rare	Liver failure, severe allergic reactions
Not known	Diabetes mellitus, memory disturbances, peripheral neuropathy, immune-mediated necrotizing myopathy

Special Features of Atorvastatin

Metabolized via CYP3A4 → higher potential for drug–drug interactions (e.g., macrolides, azole antifungals, grapefruit juice)
Broad evidence base, including high-intensity dosing (40–80 mg)
Muscle symptoms are dose- and interaction-dependent

Direct Comparison (Brief Overview)

Aspect	Rosuvastatin	Atorvastatin
CYP interactions	Low	Relevant (CYP3A4)
Potency per mg	Higher	Slightly lower
CK elevation	Slightly more frequent	Moderate
Evidence base	Very strong	Very strong
Diabetes risk	Slightly increased	Slightly increased

ESC/EAS Guideline-Level Classification of Rosuvastatin and Atorvastatin

Below is the guideline-based classification according to the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society), focusing on risk stratification, recommended intensity, LDL targets, and adverse-effect management.

Guideline Framework (ESC/EAS)

The ESC/EAS guidelines on the management of dyslipidaemias (last major update 2019, confirmed in subsequent updates) define treatment goals according to overall cardiovascular risk and recommend statins as first-line therapy.

LDL-C Target Values (Selection)

Risk category	LDL-C target
Very high risk	< 55 mg/dL and ≥ 50% reduction
High risk	< 70 mg/dL and ≥ 50% reduction
Moderate risk	< 100 mg/dL
Low risk	< 116 mg/dL

Statin Intensity According to ESC/EAS

Statins are primarily classified by percentage LDL-C reduction.

High-Intensity Statin Therapy (≥ 50% LDL-C reduction)

Statin	Dose	Guideline classification
Rosuvastatin	20–40 mg	High-intensity
Atorvastatin	40–80 mg	High-intensity

Both are equivalent first-line options for patients at high and very high cardiovascular risk.

ESC/EAS Classification: Rosuvastatin vs Atorvastatin

Aspect	Rosuvastatin	Atorvastatin
Guideline status	First line	First line
LDL-C potency	Very high	Very high
Goal achievement	Slightly more efficient per mg	Very good, dose-dependent
Interaction risk	Low	Increased (CYP3A4)
Adverse-effect profile	Comparable	Comparable
Evidence for ASCVD reduction	High	Very high

Adverse Effects in the Guideline Context

Key ESC/EAS Statements

Statin-associated muscle symptoms (SAMS):
- Occur in <5% in randomized trials
- Severe events (myopathy/rhabdomyolysis): <0.1%
Nocebo effect is clinically relevant → patient education is essential
Avoid therapy discontinuation; instead consider:
- Dose reduction
- Switching statins (e.g., atorvastatin ↔ rosuvastatin)
- Intermittent dosing
- Combination therapy with ezetimibe

Specific ESC/EAS Recommendations

Prefer rosuvastatin when:

Multiple concomitant medications (fewer interactions)
High LDL-C reduction required at low dose
Statin switch due to CYP3A4-related issues

Prefer atorvastatin when:

Broad clinical evidence base (secondary prevention)
Flexible dose titration
Established high-intensity regimens

Core Guideline Message

Rosuvastatin and atorvastatin are equally effective, evidence-based high-performance statins at the ESC/EAS guideline level.
Selection should be individualized based on risk profile, concomitant medication, tolerability, and target achievement—not primarily fear of adverse effects.

Key Safety Parameters During Statin Therapy

Liver Enzymes (ALT, AST)

Time point	Recommendation
Before therapy	Mandatory (baseline)
After initiation / dose change	After 8–12 weeks
Long-term	No routine monitoring required
If symptoms occur	Immediately (e.g., fatigue, jaundice, upper abdominal pain)

Intervention threshold:

ALT/AST > 3× ULN → pause therapy, re-evaluate

Creatine Kinase (CK)

Time point	Recommendation
Before therapy	Only in high-risk individuals
Routine monitoring	Not recommended
With muscle symptoms	Mandatory
After symptoms	Recheck after 5–7 days

Intervention threshold:

CK > 5× ULN → discontinue statin
CK > 10× ULN → emergency evaluation (exclude rhabdomyolysis)

LDL Cholesterol (Efficacy + Adherence)

Time point	Recommendation
Baseline	Mandatory
After initiation / dose adjustment	After 6–8 weeks
Stable therapy	Every 6–12 months

Primarily an efficacy, not safety, parameter—but essential for guideline adherence.

Renal Function (Creatinine, eGFR)

Time point	Recommendation
Routine	Not required
With CK elevation / myopathy	Mandatory
High-dose rosuvastatin	Reasonable (especially with pre-existing CKD)

Blood Glucose / HbA1c

Time point	Recommendation
Baseline	In high-risk individuals
Follow-up	As part of routine care

Note:

Statins may slightly increase diabetes risk
Moderate hyperglycaemia is not an indication to discontinue therapy

Risk Situations Requiring Closer Monitoring

Pre-existing muscle disorders
Renal impairment
High statin doses
Relevant drug interactions
Advanced age (>75 years)
Prior statin intolerance

ESC/EAS Guideline Core Statement

Targeted, symptom-oriented monitoring is safer and more effective than routine laboratory testing.
Excessive monitoring increases therapy discontinuation without improving safety.

SAMS (Statin-Associated Muscle Symptoms)

ESC/EAS and Study Evidence

ESC/EAS guidelines classify SAMS primarily as dose- and exposure-dependent:

Higher dose → higher systemic exposure → higher SAMS risk
Clear increase in:
- Myalgia
- CK elevation
- Myopathy1
  with increasing dose

Example (simplified):

Atorvastatin 10 mg → low SAMS risk
Atorvastatin 80 mg → significantly higher risk

Why Do SAMS Sometimes Appear “Dose-Independent”?
a) Pharmacokinetic factors

CYP inhibition (especially atorvastatin)
Transporter polymorphisms (e.g., SLCO1B1)
Renal or hepatic dysfunction
Clinically appears dose-independent but is exposure-related

b) Nocebo effect

Blinded re-exposure trials show:
- Similar symptom frequency under placebo
- Expectations play a major role
  Especially relevant with early onset and normal CK

c) Individual vulnerability

Older age
Female sex
Hypothyroidism
Vitamin D deficiency
Intense physical activity

These lower individual tolerance thresholds independent of nominal dose.

ESC/EAS Interpretation (Clinically Relevant)

Aspect	Assessment
Underlying mechanism	Dose-dependent
Clinical presentation	May appear dose-independent
Key determinant	Systemic exposure
Severe SAMS	Clearly dose-dependent
Mild myalgia	Often multifactorial

Practical Consequences (Guideline-Conform)

If SAMS occur:

Pause statin therapy (2–4 weeks)
Re-challenge with:
- lower dose or
- alternative statin (e.g., rosuvastatin instead of atorvastatin)
Consider intermittent dosing (e.g., 2–3×/week)
Combine with ezetimibe to reach LDL target

Goal: maximally tolerated statin dose, not discontinuation

Core Message

SAMS are predominantly dose-dependent, but often perceived as dose-independent due to exposure, interactions, and nocebo effects.

References (Guideline- and Evidence-Based)

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: EAS Consensus Panel Statement. Eur Heart J. 2015;36(17):1012–1022.
Stock J. Statin-associated muscle symptoms—EAS Consensus focus. Atherosclerosis. 2015;242(1):346–350.
Wood FA, et al. SAMSON Trial. N Engl J Med. 2020.
Howard JP, et al. SAMSON symptom analysis. J Am Coll Cardiol. 2021.
Herrett E, et al. StatinWISE Trial. BMJ. 2021;372:n135.
Penson PE, et al. Drucebo effect in statin therapy. J Cachexia Sarcopenia Muscle. 2018;9:1023–1033.